Titre :

Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT.

Auteur(s) :

Hirschbühl, Klaus [Auteur]
Universität Augsburg [Deutschland] = University of Augsburg [Germany] = Université d'Augsburg [Allemagne] [UNIA]
Labopin, Myriam [Auteur]
CHU Saint-Antoine [AP-HP]
Polge, Emmanuelle [Auteur]
CHU Saint-Antoine [AP-HP]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Bourhis, Jean Henri [Auteur]
Institut Gustave Roussy [IGR]
Socie, Gerard [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Forcade, Edouard [Auteur]
Hôpital Haut-Lévêque [CHU Bordeaux]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Labussière-Wallet, Hélène [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Bethge, Wolfgang [Auteur]
Eberhard Karls Universität Tübingen = University of Tübingen
Chevallier, Patrice [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Bonnet, Sarah [Auteur]
CHU Montpellier = Montpellier University Hospital
Stelljes, Matthias [Auteur]
University Hospital Münster - Universitaetsklinikum Muenster [Germany] [UKM]
Spyridonidis, Alexandros [Auteur]
General University Hospital of Patras
Peric, Zinaida [Auteur]
University of Zagreb
Brissot, Eolia [Auteur]
CHU Saint-Antoine [AP-HP]
Savani, Bipin [Auteur]
Vanderbilt University [Nashville]
Giebel, Sebastian [Auteur]
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology [MCMCC]
Schmid, Christoph [Auteur]
Universität Augsburg [Deutschland] = University of Augsburg [Germany] = Université d'Augsburg [Allemagne] [UNIA]
Ciceri, Fabio [Auteur]
IRCCS Ospedale San Raffaele [Milan, Italy]
Nagler, Arnon [Auteur]
Chaim Sheba Medical Center
Mohty, Mohamad [Auteur]
CHU Saint-Antoine [AP-HP]

Titre de la revue :

Bone Marrow Transplantation

Nom court de la revue :

Bone Marrow Transplant

Date de publication :

2023-05-07

ISSN :

1476-5365

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Allogeneic hematopoietic cell transplantation is a potentially curative treatment in high-risk acute lymphoblastic leukemia (ALL). Conditioning regimens based on ≥12 Gray total body irradiation (TBI) represent the current ...
Lire la suite >Allogeneic hematopoietic cell transplantation is a potentially curative treatment in high-risk acute lymphoblastic leukemia (ALL). Conditioning regimens based on ≥12 Gray total body irradiation (TBI) represent the current standard in patients ≤45 years, whereas elderly patients frequently receive intermediate intensity conditioning (IIC) to reduce toxicity. To evaluate the role of TBI as a backbone of IIC in ALL, a retrospective, registry-based study included patients >45 years transplanted from matched donors in first complete remission, who had received either fludarabine/TBI 8 Gy (FluTBI8, n = 262), or the most popular, irradiation-free alternative fludarabine/busulfan, comprising busulfan 6.4 mg/kg (FluBu6.4, n = 188) or 9.6 mg/kg (FluBu9.6, n = 51). At two years, overall survival (OS) was 68.5%, 57%, and 62.2%, leukemia-free survival (LFS) was 58%, 42.7%, and 45%, relapse incidence (RI) was 27.2%, 40%, and 30.9%, and non-relapse-mortality (NRM) was 23.1%, 20.7%, and 26.8% for patients receiving FluTBI8Gy, FluBu6.4, and FluBu9.6, respectively. In multivariate analysis, the risk of NRM, acute and chronic graft-versus-host disease was not influenced by conditioning. However, RI was higher after FluBu6.4 (hazard ratio [HR] [95% CI]: 1.85 [1.16–2.95]), and LFS was lower after both FluBu6.4 (HR: 1.56 [1.09–2.23]) and FluBu9.6 (HR: 1.63 [1.02–2.58]) as compared to FluTBI8. Although only resulting in a non-significant advantage in OS, this observation indicates a stronger anti-leukemic efficacy of TBI-based intermediate intensity conditioning.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-11T22:50:17Z
2024-03-04T09:58:13Z